OPIATE AND NICOTINE DEPENDENCE--MEDICATIONS AND THERAPY

阿片和尼古丁依赖——药物和治疗

• 批准号: 6175103
• 负责人: Maria A Sullivan
• 金额: $ 15.96万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6175103
• 关键词: antidepressants; behavioral /social science research tag; bupropion; clinical research; clinical trials; cognitive behavior therapy; combination chemotherapy; combination therapy; comorbidity; drug abuse chemotherapy; drug addiction; drug screening /evaluation; human subject; human therapy evaluation; interview; major depression; mental disorder diagnosis; naltrexone; nicotine; opiate alkaloid; outcomes research; schizophrenia; tobacco abuse

Heroin and nicotine dependence are two addictions for which new combined pharmacotherapy/behavioral therapy interventions are possible. The goal of this mentored clinical scientist award is to promote the developing research skills of Maria A. Sullivan, M.D., Ph.D., by providing two areas of clinical research for testing novel combined medication/therapy strategies for opiate and nicotine dependence. Dr. Sullivan, a Board-Certified Psychiatrist, has completed a successful research fellowship in the Division on Substance Use at Columbia University/New York State Psychiatric Institute (NYSPI). As a fellow, Dr. Sullivan has begun studying patterns of smoking among schizophrenic patients and carried out a pilot intervention using bupropion/behavioral therapy to treat nicotine dependence among patients with chronic psychosis. This year Dr. Sullivan has joined the staff in the Division as an Assistant Professor of Clinical Psychiatry. She is currently serving as the Co-Director for the NIDA funded grant, "Opiate Dependence: Combined Naltrexone/Behavior Therapy." In the next several years, Dr. Sullivan plans to carry out clinical treatment trials to explore novel combined pharmacotherapy/psychotherapy approaches to opiate and nicotine dependence. Her proposed research plan will enable her to develop skills in two specific areas of addiction psychiatry: (1)conducting double-blind pharmacotherapeutic trials of agents which target specific mood symptoms in opiate or nicotine dependence or withdrawal; and (2)developing manualized psychotherapies tailored to promote abstinence and relapse prevention for individuals abusing certain classes of drugs. In this way, Dr. Sullivan will be well prepared to achieve her long-term research career goal of developing treatment approaches for comorbid substance use/psychiatric disorders. Under the sponsorship and guidance of Dr. Herbert Kleber, together with the faculty and resources available at Columbia University, Dr. Sullivan's training plan combines formal course work with clinical research experience at several sites of the New York State Psychiatric Institute. She will be working closely with several preceptors to receive training in the following areas: design and methods of clinical treatment studies; controlled medication trials; developing and implementing manual-guided relapse prevention therapies for opiate and nicotine dependence in selected populations; and biostatistics and epidemiology. Her specific research plan includes double-blind placebo-controlled trials of bupropion for nicotine dependence and nefazodone with open-label naltrexone for opiate dependence. For both treatment studies, manual-guided relapse prevention therapies will be developed and implemented. Dr. Sullivan's planned research will provide her with unique training and will afford her the opportunity to develop a clinical research career focused on developing new combined medication/therapy approaches to the treatment of substance abuse disorders.

海洛因和尼古丁依赖是两种成瘾行为，可以采用新的联合药物治疗/行为治疗干预措施。 该临床科学家指导奖的目标是通过提供两个临床研究领域来测试阿片类药物和尼古丁依赖的新型联合药物/治疗策略，从而促进玛丽亚·A·沙利文医学博士、博士的研究技能的发展。 Sullivan 博士是一名委员会认证的精神病学家，已在哥伦比亚大学/纽约州精神病学研究所 (NYSPI) 药物使用部门成功完成了研究奖学金。 作为研究员，沙利文博士已开始研究精神分裂症患者的吸烟模式，并使用安非他酮/行为疗法进行试点干预，以治疗慢性精神病患者的尼古丁依赖。 今年，沙利文博士作为临床精神病学助理教授加入该部门。 她目前担任 NIDA 资助的赠款“阿片依赖：纳曲酮/行为联合疗法”的联合主任。 在接下来的几年中，沙利文博士计划进行临床治疗试验，以探索针对阿片类药物和尼古丁依赖的新型药物治疗/心理治疗联合疗法。 她提出的研究计划将使她能够发展成瘾精神病学两个特定领域的技能：（1）针对阿片类或尼古丁依赖或戒断中特定情绪症状的药物进行双盲药物治疗试验； (2) 开发专门的手动心理疗法，以促进滥用某些类别药物的个人戒毒和预防复发。 通过这种方式，沙利文博士将为实现她的长期研究职业目标做好充分准备，即开发针对共病药物使用/精神疾病的治疗方法。 在 Herbert Kleber 博士的赞助和指导下，以及哥伦比亚大学现有的师资和资源，Sullivan 博士的培训计划将正式课程工作与纽约州精神病学研究所多个地点的临床研究经验结合起来。 她将与几位导师密切合作，接受以下领域的培训：临床治疗研究的设计和方法；对照药物试验；制定和实施针对特定人群的阿片和尼古丁依赖的人工指导复发预防疗法；以及生物统计学和流行病学。 她的具体研究计划包括安非他酮治疗尼古丁依赖的双盲安慰剂对照试验和奈法唑酮与开放标签纳曲酮治疗阿片依赖的试验。 对于这两项治疗研究，将开发和实施手动指导的复发预防疗法。 沙利文博士计划的研究将为她提供独特的培训，并为她提供发展临床研究职业的机会，重点是开发新的组合药物/治疗方法来治疗药物滥用障碍。